Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

valrubicin MeSH Supplementary Concept Data 2026


MeSH Supplementary
valrubicin
Unique ID
C016163
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/C016163
Entry Term(s)
(2S-cis)-pentanoic acid, 2-(1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-((2,3,6-trideoxy-3-((trifluoroacetyl)amino)-alpha-L-lyxo-hexopyranosyl)oxy)-2-naphth acenyl)-2-oxoethyl ester
AD 32
AD-32
N-trifluoroacetyladriamycin 14-valerate
NSC-246131
Valstar
Valtaxin
adriamycin, trifluoroacetyl-, 14-valerate
Pharm Action
Antineoplastic Agents
Topoisomerase II Inhibitors
Registry Numbers
2C6NUM6878
0
Related Numbers
56124-62-0
Heading Mapped to
Doxorubicin / analogs & derivatives
Frequency
84
Source
Cancer Res 38(11):3944;1978
Cancer Res 39(2):360;1979
Cancer Res 39(2):448;1979
Cancer Treat Rep 62(1):105-19;1978
Cancer Treat Rep 63(5):875;1979
Cancer Treat Rep 63(5):919;1979
J Histochem Cytochem 1979;27(12):1655
J Natl Cancer Inst 61(6):1521;1978
J Pharmacol Exp Ther 204(3):696;1978
Date Introduced
1978/01/01
Last Updated
2022/09/02
valrubicin Preferred
AD 32 Narrower
NSC-246131 Narrower
Valstar Narrower
Valtaxin Narrower
page delivered in 0.005s